Home Healthcare Biotechnology Syphilis Testing Market

Syphilis Testing Market Size, Share & Trends Analysis Report By Type (Primary Syphilis, Secondary Syphilis), By Test Type (Non-treponemal tests (RPR, VDRL), Treponemal immunoassays (TPPA, TPHA), Enzyme immunoassays (ELISA) & chemiluminescent immunoassays (CLIA), Rapid diagnostic tests (lateral flow immunoassays), Molecular tests (PCR/NAAT), Multiplex STI panels, including syphilis targets), By Technology (Molecular Diagnostics, Immunoassay, Others), By Location of Testing (Laboratory Testing, Point of Care Testing) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: December 18, 2025 | Author: Debashree B | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Syphilis Testing Market, By Type 2022-2034 (USD MILLION/ Units)
    1. Primary Syphilis
    2. Secondary Syphilis
  2. Syphilis Testing Market, By Test Type 2022-2034 (USD MILLION/ Units)
    1. Non-treponemal tests (RPR, VDRL)
    2. Treponemal immunoassays (TPPA, TPHA)
    3. Enzyme immunoassays (ELISA) & chemiluminescent immunoassays (CLIA)
    4. Rapid diagnostic tests (lateral flow immunoassays)
    5. Molecular tests (PCR/NAAT)
    6. Multiplex STI panels, including syphilis targets
  3. Syphilis Testing Market, By Technology 2022-2034 (USD MILLION/ Units)
    1. Molecular Diagnostics
    2. Immunoassay
    3. Others
  4. Syphilis Testing Market, By Location of Testing 2022-2034 (USD MILLION/ Units)
    1. Laboratory Testing
      1. Commercial/Private Labs
      2. Public Health Labs
    2. Point of Care Testing
  5. Regional Syphilis Testing Market
    1. North America
      1. North America Syphilis Testing Market By Type 2022-2034 (USD MILLION/ Units)
        1. Primary Syphilis
        2. Secondary Syphilis
      2. North America Syphilis Testing Market By Test Type 2022-2034 (USD MILLION/ Units)
        1. Non-treponemal tests (RPR, VDRL)
        2. Treponemal immunoassays (TPPA, TPHA)
        3. Enzyme immunoassays (ELISA) & chemiluminescent immunoassays (CLIA)
        4. Rapid diagnostic tests (lateral flow immunoassays)
        5. Molecular tests (PCR/NAAT)
        6. Multiplex STI panels, including syphilis targets
      3. North America Syphilis Testing Market By Technology 2022-2034 (USD MILLION/ Units)
        1. Molecular Diagnostics
        2. Immunoassay
        3. Others
      4. North America Syphilis Testing Market By Location of Testing 2022-2034 (USD MILLION/ Units)
        1. Laboratory Testing
          1. Commercial/Private Labs
          2. Public Health Labs
        2. Point of Care Testing
      5. U.S.
        1. Primary Syphilis
        2. Secondary Syphilis
        3. Non-treponemal tests (RPR, VDRL)
        4. Treponemal immunoassays (TPPA, TPHA)
        5. Enzyme immunoassays (ELISA) & chemiluminescent immunoassays (CLIA)
        6. Rapid diagnostic tests (lateral flow immunoassays)
        7. Molecular tests (PCR/NAAT)
        8. Multiplex STI panels, including syphilis targets
        9. Molecular Diagnostics
        10. Immunoassay
        11. Others
        12. Laboratory Testing
          1. Commercial/Private Labs
          2. Public Health Labs
        13. Point of Care Testing
      6. Canada
        1. Primary Syphilis
        2. Secondary Syphilis
        3. Non-treponemal tests (RPR, VDRL)
        4. Treponemal immunoassays (TPPA, TPHA)
        5. Enzyme immunoassays (ELISA) & chemiluminescent immunoassays (CLIA)
        6. Rapid diagnostic tests (lateral flow immunoassays)
        7. Molecular tests (PCR/NAAT)
        8. Multiplex STI panels, including syphilis targets
        9. Molecular Diagnostics
        10. Immunoassay
        11. Others
        12. Laboratory Testing
          1. Commercial/Private Labs
          2. Public Health Labs
        13. Point of Care Testing
    2. Europe
      1. Europe Syphilis Testing Market By Type 2022-2034 (USD MILLION/ Units)
        1. Primary Syphilis
        2. Secondary Syphilis
      2. Europe Syphilis Testing Market By Test Type 2022-2034 (USD MILLION/ Units)
        1. Non-treponemal tests (RPR, VDRL)
        2. Treponemal immunoassays (TPPA, TPHA)
        3. Enzyme immunoassays (ELISA) & chemiluminescent immunoassays (CLIA)
        4. Rapid diagnostic tests (lateral flow immunoassays)
        5. Molecular tests (PCR/NAAT)
        6. Multiplex STI panels, including syphilis targets
      3. Europe Syphilis Testing Market By Technology 2022-2034 (USD MILLION/ Units)
        1. Molecular Diagnostics
        2. Immunoassay
        3. Others
      4. Europe Syphilis Testing Market By Location of Testing 2022-2034 (USD MILLION/ Units)
        1. Laboratory Testing
          1. Commercial/Private Labs
          2. Public Health Labs
        2. Point of Care Testing
      5. U.K.
        1. Primary Syphilis
        2. Secondary Syphilis
        3. Non-treponemal tests (RPR, VDRL)
        4. Treponemal immunoassays (TPPA, TPHA)
        5. Enzyme immunoassays (ELISA) & chemiluminescent immunoassays (CLIA)
        6. Rapid diagnostic tests (lateral flow immunoassays)
        7. Molecular tests (PCR/NAAT)
        8. Multiplex STI panels, including syphilis targets
        9. Molecular Diagnostics
        10. Immunoassay
        11. Others
        12. Laboratory Testing
          1. Commercial/Private Labs
          2. Public Health Labs
        13. Point of Care Testing
      6. Germany
        1. Primary Syphilis
        2. Secondary Syphilis
        3. Non-treponemal tests (RPR, VDRL)
        4. Treponemal immunoassays (TPPA, TPHA)
        5. Enzyme immunoassays (ELISA) & chemiluminescent immunoassays (CLIA)
        6. Rapid diagnostic tests (lateral flow immunoassays)
        7. Molecular tests (PCR/NAAT)
        8. Multiplex STI panels, including syphilis targets
        9. Molecular Diagnostics
        10. Immunoassay
        11. Others
        12. Laboratory Testing
          1. Commercial/Private Labs
          2. Public Health Labs
        13. Point of Care Testing
      7. France
        1. Primary Syphilis
        2. Secondary Syphilis
        3. Non-treponemal tests (RPR, VDRL)
        4. Treponemal immunoassays (TPPA, TPHA)
        5. Enzyme immunoassays (ELISA) & chemiluminescent immunoassays (CLIA)
        6. Rapid diagnostic tests (lateral flow immunoassays)
        7. Molecular tests (PCR/NAAT)
        8. Multiplex STI panels, including syphilis targets
        9. Molecular Diagnostics
        10. Immunoassay
        11. Others
        12. Laboratory Testing
          1. Commercial/Private Labs
          2. Public Health Labs
        13. Point of Care Testing
      8. Spain
        1. Primary Syphilis
        2. Secondary Syphilis
        3. Non-treponemal tests (RPR, VDRL)
        4. Treponemal immunoassays (TPPA, TPHA)
        5. Enzyme immunoassays (ELISA) & chemiluminescent immunoassays (CLIA)
        6. Rapid diagnostic tests (lateral flow immunoassays)
        7. Molecular tests (PCR/NAAT)
        8. Multiplex STI panels, including syphilis targets
        9. Molecular Diagnostics
        10. Immunoassay
        11. Others
        12. Laboratory Testing
          1. Commercial/Private Labs
          2. Public Health Labs
        13. Point of Care Testing
      9. Italy
        1. Primary Syphilis
        2. Secondary Syphilis
        3. Non-treponemal tests (RPR, VDRL)
        4. Treponemal immunoassays (TPPA, TPHA)
        5. Enzyme immunoassays (ELISA) & chemiluminescent immunoassays (CLIA)
        6. Rapid diagnostic tests (lateral flow immunoassays)
        7. Molecular tests (PCR/NAAT)
        8. Multiplex STI panels, including syphilis targets
        9. Molecular Diagnostics
        10. Immunoassay
        11. Others
        12. Laboratory Testing
          1. Commercial/Private Labs
          2. Public Health Labs
        13. Point of Care Testing
      10. Russia
        1. Primary Syphilis
        2. Secondary Syphilis
        3. Non-treponemal tests (RPR, VDRL)
        4. Treponemal immunoassays (TPPA, TPHA)
        5. Enzyme immunoassays (ELISA) & chemiluminescent immunoassays (CLIA)
        6. Rapid diagnostic tests (lateral flow immunoassays)
        7. Molecular tests (PCR/NAAT)
        8. Multiplex STI panels, including syphilis targets
        9. Molecular Diagnostics
        10. Immunoassay
        11. Others
        12. Laboratory Testing
          1. Commercial/Private Labs
          2. Public Health Labs
        13. Point of Care Testing
      11. Nordic
        1. Primary Syphilis
        2. Secondary Syphilis
        3. Non-treponemal tests (RPR, VDRL)
        4. Treponemal immunoassays (TPPA, TPHA)
        5. Enzyme immunoassays (ELISA) & chemiluminescent immunoassays (CLIA)
        6. Rapid diagnostic tests (lateral flow immunoassays)
        7. Molecular tests (PCR/NAAT)
        8. Multiplex STI panels, including syphilis targets
        9. Molecular Diagnostics
        10. Immunoassay
        11. Others
        12. Laboratory Testing
          1. Commercial/Private Labs
          2. Public Health Labs
        13. Point of Care Testing
      12. Benelux
        1. Primary Syphilis
        2. Secondary Syphilis
        3. Non-treponemal tests (RPR, VDRL)
        4. Treponemal immunoassays (TPPA, TPHA)
        5. Enzyme immunoassays (ELISA) & chemiluminescent immunoassays (CLIA)
        6. Rapid diagnostic tests (lateral flow immunoassays)
        7. Molecular tests (PCR/NAAT)
        8. Multiplex STI panels, including syphilis targets
        9. Molecular Diagnostics
        10. Immunoassay
        11. Others
        12. Laboratory Testing
          1. Commercial/Private Labs
          2. Public Health Labs
        13. Point of Care Testing
      13. Rest of Europe
        1. Primary Syphilis
        2. Secondary Syphilis
        3. Non-treponemal tests (RPR, VDRL)
        4. Treponemal immunoassays (TPPA, TPHA)
        5. Enzyme immunoassays (ELISA) & chemiluminescent immunoassays (CLIA)
        6. Rapid diagnostic tests (lateral flow immunoassays)
        7. Molecular tests (PCR/NAAT)
        8. Multiplex STI panels, including syphilis targets
        9. Molecular Diagnostics
        10. Immunoassay
        11. Others
        12. Laboratory Testing
          1. Commercial/Private Labs
          2. Public Health Labs
        13. Point of Care Testing
    3. APAC
      1. APAC Syphilis Testing Market By Type 2022-2034 (USD MILLION/ Units)
        1. Primary Syphilis
        2. Secondary Syphilis
      2. APAC Syphilis Testing Market By Test Type 2022-2034 (USD MILLION/ Units)
        1. Non-treponemal tests (RPR, VDRL)
        2. Treponemal immunoassays (TPPA, TPHA)
        3. Enzyme immunoassays (ELISA) & chemiluminescent immunoassays (CLIA)
        4. Rapid diagnostic tests (lateral flow immunoassays)
        5. Molecular tests (PCR/NAAT)
        6. Multiplex STI panels, including syphilis targets
      3. APAC Syphilis Testing Market By Technology 2022-2034 (USD MILLION/ Units)
        1. Molecular Diagnostics
        2. Immunoassay
        3. Others
      4. APAC Syphilis Testing Market By Location of Testing 2022-2034 (USD MILLION/ Units)
        1. Laboratory Testing
          1. Commercial/Private Labs
          2. Public Health Labs
        2. Point of Care Testing
      5. China
        1. Primary Syphilis
        2. Secondary Syphilis
        3. Non-treponemal tests (RPR, VDRL)
        4. Treponemal immunoassays (TPPA, TPHA)
        5. Enzyme immunoassays (ELISA) & chemiluminescent immunoassays (CLIA)
        6. Rapid diagnostic tests (lateral flow immunoassays)
        7. Molecular tests (PCR/NAAT)
        8. Multiplex STI panels, including syphilis targets
        9. Molecular Diagnostics
        10. Immunoassay
        11. Others
        12. Laboratory Testing
          1. Commercial/Private Labs
          2. Public Health Labs
        13. Point of Care Testing
      6. Korea
        1. Primary Syphilis
        2. Secondary Syphilis
        3. Non-treponemal tests (RPR, VDRL)
        4. Treponemal immunoassays (TPPA, TPHA)
        5. Enzyme immunoassays (ELISA) & chemiluminescent immunoassays (CLIA)
        6. Rapid diagnostic tests (lateral flow immunoassays)
        7. Molecular tests (PCR/NAAT)
        8. Multiplex STI panels, including syphilis targets
        9. Molecular Diagnostics
        10. Immunoassay
        11. Others
        12. Laboratory Testing
          1. Commercial/Private Labs
          2. Public Health Labs
        13. Point of Care Testing
      7. Japan
        1. Primary Syphilis
        2. Secondary Syphilis
        3. Non-treponemal tests (RPR, VDRL)
        4. Treponemal immunoassays (TPPA, TPHA)
        5. Enzyme immunoassays (ELISA) & chemiluminescent immunoassays (CLIA)
        6. Rapid diagnostic tests (lateral flow immunoassays)
        7. Molecular tests (PCR/NAAT)
        8. Multiplex STI panels, including syphilis targets
        9. Molecular Diagnostics
        10. Immunoassay
        11. Others
        12. Laboratory Testing
          1. Commercial/Private Labs
          2. Public Health Labs
        13. Point of Care Testing
      8. India
        1. Primary Syphilis
        2. Secondary Syphilis
        3. Non-treponemal tests (RPR, VDRL)
        4. Treponemal immunoassays (TPPA, TPHA)
        5. Enzyme immunoassays (ELISA) & chemiluminescent immunoassays (CLIA)
        6. Rapid diagnostic tests (lateral flow immunoassays)
        7. Molecular tests (PCR/NAAT)
        8. Multiplex STI panels, including syphilis targets
        9. Molecular Diagnostics
        10. Immunoassay
        11. Others
        12. Laboratory Testing
          1. Commercial/Private Labs
          2. Public Health Labs
        13. Point of Care Testing
      9. Australia
        1. Primary Syphilis
        2. Secondary Syphilis
        3. Non-treponemal tests (RPR, VDRL)
        4. Treponemal immunoassays (TPPA, TPHA)
        5. Enzyme immunoassays (ELISA) & chemiluminescent immunoassays (CLIA)
        6. Rapid diagnostic tests (lateral flow immunoassays)
        7. Molecular tests (PCR/NAAT)
        8. Multiplex STI panels, including syphilis targets
        9. Molecular Diagnostics
        10. Immunoassay
        11. Others
        12. Laboratory Testing
          1. Commercial/Private Labs
          2. Public Health Labs
        13. Point of Care Testing
      10. Taiwan
        1. Primary Syphilis
        2. Secondary Syphilis
        3. Non-treponemal tests (RPR, VDRL)
        4. Treponemal immunoassays (TPPA, TPHA)
        5. Enzyme immunoassays (ELISA) & chemiluminescent immunoassays (CLIA)
        6. Rapid diagnostic tests (lateral flow immunoassays)
        7. Molecular tests (PCR/NAAT)
        8. Multiplex STI panels, including syphilis targets
        9. Molecular Diagnostics
        10. Immunoassay
        11. Others
        12. Laboratory Testing
          1. Commercial/Private Labs
          2. Public Health Labs
        13. Point of Care Testing
      11. South East Asia
        1. Primary Syphilis
        2. Secondary Syphilis
        3. Non-treponemal tests (RPR, VDRL)
        4. Treponemal immunoassays (TPPA, TPHA)
        5. Enzyme immunoassays (ELISA) & chemiluminescent immunoassays (CLIA)
        6. Rapid diagnostic tests (lateral flow immunoassays)
        7. Molecular tests (PCR/NAAT)
        8. Multiplex STI panels, including syphilis targets
        9. Molecular Diagnostics
        10. Immunoassay
        11. Others
        12. Laboratory Testing
          1. Commercial/Private Labs
          2. Public Health Labs
        13. Point of Care Testing
      12. Rest of Asia-Pacific
        1. Primary Syphilis
        2. Secondary Syphilis
        3. Non-treponemal tests (RPR, VDRL)
        4. Treponemal immunoassays (TPPA, TPHA)
        5. Enzyme immunoassays (ELISA) & chemiluminescent immunoassays (CLIA)
        6. Rapid diagnostic tests (lateral flow immunoassays)
        7. Molecular tests (PCR/NAAT)
        8. Multiplex STI panels, including syphilis targets
        9. Molecular Diagnostics
        10. Immunoassay
        11. Others
        12. Laboratory Testing
          1. Commercial/Private Labs
          2. Public Health Labs
        13. Point of Care Testing
    4. Middle East and Africa
      1. Middle East and Africa Syphilis Testing Market By Type 2022-2034 (USD MILLION/ Units)
        1. Primary Syphilis
        2. Secondary Syphilis
      2. Middle East and Africa Syphilis Testing Market By Test Type 2022-2034 (USD MILLION/ Units)
        1. Non-treponemal tests (RPR, VDRL)
        2. Treponemal immunoassays (TPPA, TPHA)
        3. Enzyme immunoassays (ELISA) & chemiluminescent immunoassays (CLIA)
        4. Rapid diagnostic tests (lateral flow immunoassays)
        5. Molecular tests (PCR/NAAT)
        6. Multiplex STI panels, including syphilis targets
      3. Middle East and Africa Syphilis Testing Market By Technology 2022-2034 (USD MILLION/ Units)
        1. Molecular Diagnostics
        2. Immunoassay
        3. Others
      4. Middle East and Africa Syphilis Testing Market By Location of Testing 2022-2034 (USD MILLION/ Units)
        1. Laboratory Testing
          1. Commercial/Private Labs
          2. Public Health Labs
        2. Point of Care Testing
      5. UAE
        1. Primary Syphilis
        2. Secondary Syphilis
        3. Non-treponemal tests (RPR, VDRL)
        4. Treponemal immunoassays (TPPA, TPHA)
        5. Enzyme immunoassays (ELISA) & chemiluminescent immunoassays (CLIA)
        6. Rapid diagnostic tests (lateral flow immunoassays)
        7. Molecular tests (PCR/NAAT)
        8. Multiplex STI panels, including syphilis targets
        9. Molecular Diagnostics
        10. Immunoassay
        11. Others
        12. Laboratory Testing
          1. Commercial/Private Labs
          2. Public Health Labs
        13. Point of Care Testing
      6. Turkey
        1. Primary Syphilis
        2. Secondary Syphilis
        3. Non-treponemal tests (RPR, VDRL)
        4. Treponemal immunoassays (TPPA, TPHA)
        5. Enzyme immunoassays (ELISA) & chemiluminescent immunoassays (CLIA)
        6. Rapid diagnostic tests (lateral flow immunoassays)
        7. Molecular tests (PCR/NAAT)
        8. Multiplex STI panels, including syphilis targets
        9. Molecular Diagnostics
        10. Immunoassay
        11. Others
        12. Laboratory Testing
          1. Commercial/Private Labs
          2. Public Health Labs
        13. Point of Care Testing
      7. Saudi Arabia
        1. Primary Syphilis
        2. Secondary Syphilis
        3. Non-treponemal tests (RPR, VDRL)
        4. Treponemal immunoassays (TPPA, TPHA)
        5. Enzyme immunoassays (ELISA) & chemiluminescent immunoassays (CLIA)
        6. Rapid diagnostic tests (lateral flow immunoassays)
        7. Molecular tests (PCR/NAAT)
        8. Multiplex STI panels, including syphilis targets
        9. Molecular Diagnostics
        10. Immunoassay
        11. Others
        12. Laboratory Testing
          1. Commercial/Private Labs
          2. Public Health Labs
        13. Point of Care Testing
      8. South Africa
        1. Primary Syphilis
        2. Secondary Syphilis
        3. Non-treponemal tests (RPR, VDRL)
        4. Treponemal immunoassays (TPPA, TPHA)
        5. Enzyme immunoassays (ELISA) & chemiluminescent immunoassays (CLIA)
        6. Rapid diagnostic tests (lateral flow immunoassays)
        7. Molecular tests (PCR/NAAT)
        8. Multiplex STI panels, including syphilis targets
        9. Molecular Diagnostics
        10. Immunoassay
        11. Others
        12. Laboratory Testing
          1. Commercial/Private Labs
          2. Public Health Labs
        13. Point of Care Testing
      9. Egypt
        1. Primary Syphilis
        2. Secondary Syphilis
        3. Non-treponemal tests (RPR, VDRL)
        4. Treponemal immunoassays (TPPA, TPHA)
        5. Enzyme immunoassays (ELISA) & chemiluminescent immunoassays (CLIA)
        6. Rapid diagnostic tests (lateral flow immunoassays)
        7. Molecular tests (PCR/NAAT)
        8. Multiplex STI panels, including syphilis targets
        9. Molecular Diagnostics
        10. Immunoassay
        11. Others
        12. Laboratory Testing
          1. Commercial/Private Labs
          2. Public Health Labs
        13. Point of Care Testing
      10. Nigeria
        1. Primary Syphilis
        2. Secondary Syphilis
        3. Non-treponemal tests (RPR, VDRL)
        4. Treponemal immunoassays (TPPA, TPHA)
        5. Enzyme immunoassays (ELISA) & chemiluminescent immunoassays (CLIA)
        6. Rapid diagnostic tests (lateral flow immunoassays)
        7. Molecular tests (PCR/NAAT)
        8. Multiplex STI panels, including syphilis targets
        9. Molecular Diagnostics
        10. Immunoassay
        11. Others
        12. Laboratory Testing
          1. Commercial/Private Labs
          2. Public Health Labs
        13. Point of Care Testing
      11. Rest of MEA
        1. Primary Syphilis
        2. Secondary Syphilis
        3. Non-treponemal tests (RPR, VDRL)
        4. Treponemal immunoassays (TPPA, TPHA)
        5. Enzyme immunoassays (ELISA) & chemiluminescent immunoassays (CLIA)
        6. Rapid diagnostic tests (lateral flow immunoassays)
        7. Molecular tests (PCR/NAAT)
        8. Multiplex STI panels, including syphilis targets
        9. Molecular Diagnostics
        10. Immunoassay
        11. Others
        12. Laboratory Testing
          1. Commercial/Private Labs
          2. Public Health Labs
        13. Point of Care Testing
    5. LATAM
      1. LATAM Syphilis Testing Market By Type 2022-2034 (USD MILLION/ Units)
        1. Primary Syphilis
        2. Secondary Syphilis
      2. LATAM Syphilis Testing Market By Test Type 2022-2034 (USD MILLION/ Units)
        1. Non-treponemal tests (RPR, VDRL)
        2. Treponemal immunoassays (TPPA, TPHA)
        3. Enzyme immunoassays (ELISA) & chemiluminescent immunoassays (CLIA)
        4. Rapid diagnostic tests (lateral flow immunoassays)
        5. Molecular tests (PCR/NAAT)
        6. Multiplex STI panels, including syphilis targets
      3. LATAM Syphilis Testing Market By Technology 2022-2034 (USD MILLION/ Units)
        1. Molecular Diagnostics
        2. Immunoassay
        3. Others
      4. LATAM Syphilis Testing Market By Location of Testing 2022-2034 (USD MILLION/ Units)
        1. Laboratory Testing
          1. Commercial/Private Labs
          2. Public Health Labs
        2. Point of Care Testing
      5. Brazil
        1. Primary Syphilis
        2. Secondary Syphilis
        3. Non-treponemal tests (RPR, VDRL)
        4. Treponemal immunoassays (TPPA, TPHA)
        5. Enzyme immunoassays (ELISA) & chemiluminescent immunoassays (CLIA)
        6. Rapid diagnostic tests (lateral flow immunoassays)
        7. Molecular tests (PCR/NAAT)
        8. Multiplex STI panels, including syphilis targets
        9. Molecular Diagnostics
        10. Immunoassay
        11. Others
        12. Laboratory Testing
          1. Commercial/Private Labs
          2. Public Health Labs
        13. Point of Care Testing
      6. Mexico
        1. Primary Syphilis
        2. Secondary Syphilis
        3. Non-treponemal tests (RPR, VDRL)
        4. Treponemal immunoassays (TPPA, TPHA)
        5. Enzyme immunoassays (ELISA) & chemiluminescent immunoassays (CLIA)
        6. Rapid diagnostic tests (lateral flow immunoassays)
        7. Molecular tests (PCR/NAAT)
        8. Multiplex STI panels, including syphilis targets
        9. Molecular Diagnostics
        10. Immunoassay
        11. Others
        12. Laboratory Testing
          1. Commercial/Private Labs
          2. Public Health Labs
        13. Point of Care Testing
      7. Argentina
        1. Primary Syphilis
        2. Secondary Syphilis
        3. Non-treponemal tests (RPR, VDRL)
        4. Treponemal immunoassays (TPPA, TPHA)
        5. Enzyme immunoassays (ELISA) & chemiluminescent immunoassays (CLIA)
        6. Rapid diagnostic tests (lateral flow immunoassays)
        7. Molecular tests (PCR/NAAT)
        8. Multiplex STI panels, including syphilis targets
        9. Molecular Diagnostics
        10. Immunoassay
        11. Others
        12. Laboratory Testing
          1. Commercial/Private Labs
          2. Public Health Labs
        13. Point of Care Testing
      8. Chile
        1. Primary Syphilis
        2. Secondary Syphilis
        3. Non-treponemal tests (RPR, VDRL)
        4. Treponemal immunoassays (TPPA, TPHA)
        5. Enzyme immunoassays (ELISA) & chemiluminescent immunoassays (CLIA)
        6. Rapid diagnostic tests (lateral flow immunoassays)
        7. Molecular tests (PCR/NAAT)
        8. Multiplex STI panels, including syphilis targets
        9. Molecular Diagnostics
        10. Immunoassay
        11. Others
        12. Laboratory Testing
          1. Commercial/Private Labs
          2. Public Health Labs
        13. Point of Care Testing
      9. Colombia
        1. Primary Syphilis
        2. Secondary Syphilis
        3. Non-treponemal tests (RPR, VDRL)
        4. Treponemal immunoassays (TPPA, TPHA)
        5. Enzyme immunoassays (ELISA) & chemiluminescent immunoassays (CLIA)
        6. Rapid diagnostic tests (lateral flow immunoassays)
        7. Molecular tests (PCR/NAAT)
        8. Multiplex STI panels, including syphilis targets
        9. Molecular Diagnostics
        10. Immunoassay
        11. Others
        12. Laboratory Testing
          1. Commercial/Private Labs
          2. Public Health Labs
        13. Point of Care Testing
      10. Rest of LATAM
        1. Primary Syphilis
        2. Secondary Syphilis
        3. Non-treponemal tests (RPR, VDRL)
        4. Treponemal immunoassays (TPPA, TPHA)
        5. Enzyme immunoassays (ELISA) & chemiluminescent immunoassays (CLIA)
        6. Rapid diagnostic tests (lateral flow immunoassays)
        7. Molecular tests (PCR/NAAT)
        8. Multiplex STI panels, including syphilis targets
        9. Molecular Diagnostics
        10. Immunoassay
        11. Others
        12. Laboratory Testing
          1. Commercial/Private Labs
          2. Public Health Labs
        13. Point of Care Testing
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.